Key result
Dapagliflozin improves short-term mitral regurgitation parameters in patients with functional mitral regurgitation.
Why the study?
The effect of dapagliflozin on the progression or improvement of regurgitation in valvular heart disease was uncertain.
Does dapagliflozin improve regurgitation parameters in patients with valvular heart disease?
Does dapagliflozin improve regurgitation parameters in patients with valvular heart disease?
Dapagliflozin shows short-term improvement in mitral regurgitation parameters among patients with functional mitral regurgitation, though its impact on other valvular diseases requires further study.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for functional mitral regurgitation; leaves open effects across other valvular diseases.
Evidence shows dapagliflozin can significantly improve mitral regurgitation parameters in the short term for patients with functional mitral regurgitation. Its effects on other types of valvular heart disease remain unclear, indicating the need for further research.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. Dapagliflozin significantly improves short-term mitral regurgitation parameters in patients with functional mitral regurgitation, though its effects on other valvular heart diseases remain unclear.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: